Tesaro appoints new board member
This article was originally published in Scrip
Oncology-focused biopharmaceutical company, Tesaro, has appointed Dr James Armitage to its board of directors – increasing the number of independent directors on the board to six. Dr Armitage is currently the Joe Shapiro chair for the study of oncology and clinical research at the University of Nebraska Medical Center, Omaha. He has also served as president of the American Society of Clinical Oncology and the American Society for Blood and Marrow Transplantation.
You may also be interested in...
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.